leflunomide has been researched along with Rheumatism in 16 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Maternal exposure to leflunomide during pregnancy was not associated with statistically significant increased risk of MCMs, prematurity, LBW or spontaneous abortions." | 7.88 | Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. ( Bérard, A; Colilla, S; Shui, I; Zhao, JP, 2018) |
| "All 16 of the pregnancies with leflunomide exposure during pregnancy and 27 (93%) of the pregnancies with exposure prior to conception resulted in liveborn infants." | 7.78 | Pregnancy outcome in women exposed to leflunomide before or during pregnancy. ( Braddock, SR; Cassina, M; Chambers, CD; Jimenez, JL; Johnson, DL; Jones, KL; Luo, YJ; Mirrasoul, N; Robinson, LK; Salas, E; Xu, R, 2012) |
| "Maternal exposure to leflunomide during pregnancy was not associated with statistically significant increased risk of MCMs, prematurity, LBW or spontaneous abortions." | 3.88 | Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. ( Bérard, A; Colilla, S; Shui, I; Zhao, JP, 2018) |
| "All 16 of the pregnancies with leflunomide exposure during pregnancy and 27 (93%) of the pregnancies with exposure prior to conception resulted in liveborn infants." | 3.78 | Pregnancy outcome in women exposed to leflunomide before or during pregnancy. ( Braddock, SR; Cassina, M; Chambers, CD; Jimenez, JL; Johnson, DL; Jones, KL; Luo, YJ; Mirrasoul, N; Robinson, LK; Salas, E; Xu, R, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Auroux, M | 1 |
| Laurent, B | 1 |
| Coste, B | 1 |
| Massy, E | 1 |
| Mercier, A | 1 |
| Durieu, I | 1 |
| Confavreux, CB | 1 |
| Lega, JC | 1 |
| Mainbourg, S | 1 |
| Coury, F | 1 |
| Nakafero, G | 1 |
| Grainge, MJ | 1 |
| Card, T | 1 |
| Mallen, CD | 1 |
| Zhang, W | 1 |
| Doherty, M | 1 |
| Taal, MW | 1 |
| Aithal, GP | 1 |
| Abhishek, A | 1 |
| Bérard, A | 1 |
| Zhao, JP | 1 |
| Shui, I | 1 |
| Colilla, S | 1 |
| Oliveira, AC | 1 |
| Mota, LM | 1 |
| Santos-Neto, LL | 1 |
| Simões, M | 1 |
| Martins-Filho, OA | 1 |
| Tauil, PL | 1 |
| Mimori, T | 1 |
| Cassina, M | 1 |
| Johnson, DL | 1 |
| Robinson, LK | 1 |
| Braddock, SR | 1 |
| Xu, R | 1 |
| Jimenez, JL | 1 |
| Mirrasoul, N | 1 |
| Salas, E | 1 |
| Luo, YJ | 1 |
| Jones, KL | 1 |
| Chambers, CD | 1 |
| Miller, AV | 1 |
| Ranatunga, SK | 1 |
| Schiemann, U | 1 |
| Kellner, H | 1 |
| Mayer, DF | 1 |
| Kushwaha, SS | 1 |
| Chira, P | 1 |
| Sandborg, CI | 1 |
| Kremer, JM | 1 |
| Metzler, C | 1 |
| Arlt, AC | 1 |
| Gross, WL | 1 |
| Brandt, J | 1 |
| Finn, S | 1 |
| Bond, J | 1 |
| McCarthy, D | 1 |
| Sheahan, K | 1 |
| Quinn, C | 1 |
| Østensen, M | 1 |
| von Esebeck, M | 1 |
| Villiger, PM | 1 |
| Glück, T | 1 |
| Müller-Ladner, U | 1 |
| Robinson, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area[NCT03430388] | 600 participants (Actual) | Interventional | 2018-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for leflunomide and Rheumatism
| Article | Year |
|---|---|
Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis.
Topics: Abatacept; Adult; Aged; Antirheumatic Agents; Cohort Studies; COVID-19; COVID-19 Vaccines; Humans; I | 2022 |
[Immunosuppressants].
Topics: Azathioprine; Calcineurin Inhibitors; Collagen Diseases; Cyclophosphamide; Cyclosporine; Humans; Imm | 2009 |
Immunotherapies in rheumatologic disorders.
Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monocl | 2012 |
[Gastrointestinal side effects in the therapy of rheumatologic diseases].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic | 2002 |
Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases.
Topics: Autoimmune Diseases; Azathioprine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 2003 |
Novel therapies in pediatric rheumatic diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Deri | 2003 |
Rheumatological creativity and leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Isoxazoles; Leflunomide; Rheumatic Diseases | 2004 |
[Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Azathioprine; Biological Pro | 2007 |
8 other studies available for leflunomide and Rheumatism
| Article | Year |
|---|---|
What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?
Topics: Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Female; Humans; Immunosuppressive Age | 2021 |
Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Antirheumatic Agents; Female; Humans; Inf | 2018 |
Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumat | 2015 |
Pregnancy outcome in women exposed to leflunomide before or during pregnancy.
Topics: Abnormalities, Drug-Induced; Antirheumatic Agents; Chondrodysplasia Punctata; Ductus Arteriosus, Pat | 2012 |
Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide.
Topics: Adult; Aged; Antirheumatic Agents; Female; Humans; Isoxazoles; Leflunomide; Male; Middle Aged; Perip | 2005 |
Angioinvasive aspergillosis presenting as neutropenic colitis.
Topics: Adalimumab; Adjuvants, Immunologic; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodi | 2006 |
Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Congenital Abnormalities; Cont | 2007 |
Clinical therapeutics.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase | 1999 |